GlassScriptPhysician profile
Austin J Ma
NPI 1598700627
$4,741.36
in general payments reported to CMS, 2019-2025
38 companies · $998 in 2025
The $998 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $27.58 · 2021: $225 · 2022: $580 · 2023: $1,155 · 2024: $1,416 · 2025: $998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,163 · Education: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,162.77 |
| Education | $406.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $723.46 | 2019-2025 | |
| Beigene USA, INC. | $619.42 | 2021-2025 | Brukinsa |
| Pfizer INC. | $379.81 | 2019-2025 | |
| Astellas Pharma US INC | $248.07 | 2023-2024 | Xtandi |
| Array Biopharma INC | $234.56 | 2019-2025 | Mektovi, Braftovi, Tukysa |
| Astrazeneca Pharmaceuticals LP | $222.54 | 2019-2024 | Calquence |
| Beone Medicines USA, INC. | $221.07 | 2025 | Brukinsa |
| Abbvie INC. | $195.68 | 2023-2025 | |
| Glaxosmithkline, LLC. | $192.47 | 2022-2024 | Jemperli, Zejula, Shingrix |
| Lilly USA, LLC | $181.66 | 2021-2024 | Jaypirca, Verzenio, Retevmo |
| Sobi, INC | $161.23 | 2023-2025 | |
| Seagen INC. | $122.24 | 2023-2025 | Tukysa |
| Gilead Sciences, INC. | $100.45 | 2023-2024 | Trodelvy |
| Puma Biotechnology, INC. | $99.21 | 2019-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $83.48 | 2019-2023 | Imbruvica |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.